Ovid drug reduces seizure frequency in two rare forms of epilepsy, according to early Phase II data October 1, 2020 Auto Bot BioPharma, biopharma nl, epilepsy, New York, ovid therapeutics, Takeda Pharmaceutical 0 The data from a Phase II pilot and an extension study of soticlestat, also known as OV935 or TAK-935, showed short- and long-term reductions of seizure frequency in patients with CDKL5 deficiency disorder and Dup15q syndrome.